Bristol Has “Critical Mass” In R&D And Sales; Faces Tough 2004
Executive Summary
Bristol-Myers Squibb believes it has the "critical mass" in R&D and sales to continue as a stand-alone company, CEO Peter Dolan said Jan. 29 during the company's year end earnings call
You may also be interested in...
Therapeutic Area Focus Could Pay Off In Biomarker Discovery, Bristol VP Says
Having an R&D focus on targeted therapeutic areas could be beneficial in terms of developing biomarkers, according to a Bristol-Myers Squibb exec
Therapeutic Area Focus Could Pay Off In Biomarker Discovery, Bristol VP Says
Having an R&D focus on targeted therapeutic areas could be beneficial in terms of developing biomarkers, according to a Bristol-Myers Squibb exec
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III